Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Surface imaging Clear all
Suspended No phase listed Observational Accepts healthy volunteers

Prospective Study to Validate the Imaging Biomarker for NCP (R33)

NCT05653921
View directory record Official record
Conditions
Dry Eye Syndromes, Corneal Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
323
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

NCT05969496
View directory record Official record
Conditions
Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
Interventions
Axitinib, Pembrolizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers

NCT02550210
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Cancer Locator (BCL)
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 3, 2026, 5:34 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT02834013
View directory record Official record
Conditions
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1006
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01896999
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
479
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Effects of Hard Gum Chewing on Facial Soft Tissue Morphology

NCT07726511
View directory record Official record
Conditions
Face
Interventions
Hard Gum Chewing
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
20 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

NCT02322528
View directory record Official record
Conditions
Sjogren's Disease
Interventions
Administration of Lotemax
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Exciflex Electroceutical Banadage for Chronic Wound Therapy

NCT04887688
View directory record Official record
Conditions
Chronic Wound, Diabetes, Spinal Cord Injury, Ischemic Wound
Interventions
exciflex
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Terminated Not applicable Interventional

A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)

NCT01821443
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic radiosurgery (SRS)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Histological Analysis Following Ulthera System Treatment for Hyperhidrosis

NCT01708551
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Ulthera System Treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Sep 3, 2026, 5:34 PM EDT
Terminated No phase listed Observational

3-Dimensional Form and Soft Tissue Biomechanics of the Breast

NCT00502814
View directory record Official record
Conditions
Breast Cancer
Interventions
3-D Optical Surface Scan, Mechanical Testing, Cutaneous Ultrasound, Breast MRI and/or CT
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy

NCT03799523
View directory record Official record
Conditions
Breast Cancer
Interventions
Temporary skin markings, Surface imaging
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Tissue Oxygenation Measurement Using Multimodal Devices

NCT05784103
View directory record Official record
Conditions
Oxygen Saturation
Interventions
Clarifi Modulum, Perimed PeriFlux 5000, Apple Watch Oxygen Sensor, Innovo iP 900AP
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 3, 2026, 5:34 PM EDT
Active, not recruiting No phase listed Observational

Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes

NCT05593523
View directory record Official record
Conditions
Burn Wound
Interventions
Indocyanine green (ICG), Clinical Fluorescence Imaging Device
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Longitudinal Spatial Frequency Domain Imaging Study

NCT05672992
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
Spatial-frequency domain imaging (SFDI)
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Multi-modal Imaging of Myofascial Pain - Phase 2

NCT07322445
View directory record Official record
Conditions
Myofascial Pain
Interventions
50/50 Mixture of Lidocaine 1% injection + Bupivacaine 0.25% Injectable Solution, Dry Needling
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Phase 1Phase 2 Interventional

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

NCT03834272
View directory record Official record
Conditions
Peritoneal Metastases
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer

NCT02549534
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Axon Reflexes, Axon Flares, Self-Reported Signs & Symptoms of CIPN
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Transcranial Alternating Current Stimulation (tACS) in Stuttering

NCT06740968
View directory record Official record
Conditions
Stuttering, Adult, Stuttering, Childhood, Stuttering, Developmental
Interventions
transcranial alternating current stimulation (tACS)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 3, 2026, 5:34 PM EDT
Terminated Phase 1 Interventional

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

NCT04967196
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

NCT07155317
View directory record Official record
Conditions
Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Acral Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 3, 2026, 5:34 PM EDT